Cardiovascular safety of degarelix: Results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer

Journal of Urology

Volumn 184, Issue 6, 2010, Pages 2313-2319

  Smith, Matthew R ^a   Klotz, Laurence ^b   Persson, Bo Eric ^c   Olesen, Tine Kold ^c   Wilde, Arthur A M ^d  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c Ferring Pharmaceuticals AS   (Denmark)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adenocarcinoma; Drug monitoring; Gonadotropin releasing hormone

Indexed keywords

DEGARELIX; GLUCOSE; LEUPRORELIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATRIOVENTRICULAR CONDUCTION; BRADYCARDIA; CANCER THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE URINE LEVEL; HEART ARREST; HEART BUNDLE BRANCH BLOCK; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR ATHEROSCLEROSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 78349311655     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.08.012     Document Type: Article

References (20)

1. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448
2. P.J. Saylor, and M.R. Smith Metabolic complications of androgen deprivation therapy for prostate cancer J Urol 181 2009 1998
3. M.R. Smith Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors Curr Urol Rep 9 2008 197
4. M.B. Garnick, C.M. Pratt, and M. Campion The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix J Clin Oncol, suppl. 22 2004 abstract 4578
5. P. Hakimian, M.J. Blute, and J. Kashanian Metabolic and cardiovascular effects of androgen deprivation therapy BJU Int 102 2008 1508
6. R.D. Stanworth, and T.H. Jones Testosterone in obesity, metabolic syndrome and type 2 diabetes Front Horm Res 37 2009 74
7. L. Klotz, L. Boccon-Gibod, and N.D. Shore The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer BJU Int 102 2008 1531
8. M. Gittelman, P.J. Pommerville, and B.E. Persson A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America J Urol 180 2008 1986
9. H. Van Poppel, B. Tombal, and J.J. de laRosette Degarelix: a novel gonadotrophin-releasing hormone (GnRH) receptor blockerresults from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer Eur Urol 54 2008 805
10. J.E. Frampton, and K.A. Lyseng-Williamson Degarelix Drugs 69 2009 1967
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs 2005 http://www.ich.org/LOB/media/MEDIA1476.pdf Accessed June 8, 2010
12. L.S. Fridericia The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease Acta Med Scand 53 1920 469
13. C. Funck-Brentano, and P. Jaillon Rate-corrected QT interval: techniques and limitations Am J Cardiol 72 1993 17B
14. P.E. Kintzel, S.L. Chase, and L.M. Schultz Increased risk of metabolic syndrome, diabetes mellitus and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer Pharmacotherapy 28 2008 1511
15. G.N. Levine, A.V. D'Amico, and P. Berger Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory forum from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology CA Cancer J Clin 60 2010 194
16. H. Bidoggia, J.P. Maciel, and N. Capalozza Sex differences on the electrocardiographic pattern of cardiac repolarization: possible role of testosterone Am Heart J 140 2000 678
17. J.S. Mitcheson hERG potassium channels and the structural basis of drug-induced arrhythmias Chem Res Toxicol 21 2008 1005
18. Ferring Pharmaceuticals A/S: Effect of FE200486 on hERG tail current recorded from stably transfected HEK293 cells. Study Report FE:200486PHA0204. Unpublished data.
19. Ferring Pharmaceuticals A/S: Study PHA0203. Unpublished data.
20. N.L. Keating, A.J. O'Malley, and S.J. Freedland Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39